Pembrolizumab (Keytruda) induced an overall response rate (ORR) of 30% (95% CI, 13%-53%) in patients with heavily pretreated, PD-L1–positive advanced esophageal carcinoma, according to findings from the phase Ib KEYNOTE-028 trial published in the Journal of Clinical Oncology.
http://www.onclive.com/web-exclusives/pembrolizumab-effective-in-esophageal-carcinoma
Pembrolizumab Effective in Esophageal Carcinoma